SpringWorks Therapeutics, Inc.
SWTXDelisted Jul 1, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001773427
SpringWorks Therapeutics, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 2, 2025; 223 institutions reported holding it in 13F filings for Q2 2025, worth $3.65B in total; Soros Fund Management was the only superinvestor holding it.
Q3 2025 vs. Q2 2025
How the institutions holding SpringWorks Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 223 | 3 | 3 | −217 |
| Shares | 77.6M | 1.83M | 40.1K | −75.8M (−99.9%) |
| Value | $3.65B | $85.9M | $2.16M | −$3.56B (−99.9%) |
3 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (0)
Institutions that held SpringWorks Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
None.
Sold out (217)
Institutions that held SpringWorks Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
Showing the largest 100 of 217 by value.
Not filed for Q3 2025 yet (3)
Institutions that held SpringWorks Therapeutics, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Norges Bank | 1,815,111 | $85.3M |
| E Fund Management Co., Ltd. | 12,693 | $596.4K |
| First Horizon Advisors, Inc. | 58 | $2.73K |